Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGD001 in Acute Ischemic Stroke (Phase 1b/2a Dose-Finding and Randomized Expansion)
2025-522455-26-00Phase 2Authorised
- Sponsor
- TargED Biopharmaceuticals
- Start
- Oct 2025
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing TGD001 arm with Placebo arm (2 arms). Primary endpoints: Symptomatic intracranial hemorrhage (sICH) and Treatment emergent adverse events (TEAEs). Planned start Oct 2025; status: authorised.
02
Drugs
TGD001
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2025-522455-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522455-26-00.